Miller fisher syndrome with positive anti-GQ1b/GT1a antibodies associated with COVID-19 infection:A case report
作者机构：Department of NeurologyHuai’an HospitalHuai’an Cancer HospitalHuai’an 223001Jiangsu ProvinceChina Department of NeurologyThe First Affiliated Hospital of Harbin Medical UniversityHarbin 150081Heilongjiang ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2024年第12卷第31期
页 面：6500-6505页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Miller fisher syndrome Guillain-Barre syndrome COVID-19 Anti-GQ1b antibody Anti-GT1a antibody Case report
摘 要：BACKGROUND Miller fisher syndrome(MFS)is a variant of Guillain-Barrésyndrome,an acute immune-mediated peripheral neuropathy that is often secondary to viral ***-ganglioside antibodies play crucial roles in the development of *** positive rate of ganglioside antibodies is exceptionally high in MFS patients,particularly for anti-GQ1b ***,the presence of other ganglioside antibodies does not exclude *** SUMMARY We present a 56-year-old female patient who suddenly developed right blepharoptosis and progressively worsening vision in both *** were flu symptoms prior to onset,and a coronavirus disease 2019 test was *** physical examination,the patient exhibited bilateral extraocular muscle paralysis,weakened reflexes in both limbs,and impaired *** cerebrospinal fluid examination results showed no obvious *** peroneal nerve F-waves were not *** anti-GD1b IgG and anti-GT1a IgG antibodies were *** patient received intravenous methylprednisolone(1000 mg/day),with the dosage gradually ***,intravenous high-dose immunoglobulin treatment was administered for 5 days(0.4 g/kg/day)from day 2 to day 6 of *** patient’s symptoms improved after treatment with immunoglobulins and *** Positive ganglioside antibodies may be used as supporting evidence for the diagnosis;however,the diagnosis of MFS is more reliant on clinical symptoms.
维普期刊数据库